AbbVie Inc (ABBV)vsDocGo Inc (DCGO)
ABBV
AbbVie Inc
$253.35
+4.20%
HEALTHCARE · Cap: $447.62B
DCGO
DocGo Inc
$0.49
-1.91%
HEALTHCARE · Cap: $54.93M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 20721% more annual revenue ($62.82B vs $301.71M). ABBV leads profitability with a 5.8% profit margin vs -62.2%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
DCGO
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.3%
Fair Value
$146.22
Current Price
$253.35
$107.13 premium
Margin of Safety
+53.4%
Fair Value
$1.56
Current Price
$0.49
$1.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -141.9% — below average capital efficiency
Revenue declined 21.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : DCGO
The strongest argument for DCGO centers on Price/Book, Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 123.6x leaves little room for execution misses.
Bear Case : DCGO
The primary concerns for DCGO are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while DCGO is a turnaround play — different risk/reward profiles.
DCGO carries more volatility with a beta of 1.00 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 36/100) and 12.4% revenue growth. DCGO offers better value entry with a 53.4% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
DocGo Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
DocGo Inc. is an innovative mobile healthcare service provider that enhances patient access and optimizes healthcare delivery through its advanced logistics and telehealth solutions. Specializing in urgent care, diagnostic testing, and health screenings, DocGo addresses critical healthcare needs across various settings while significantly improving patient experiences. With a commitment to innovation and expanding healthcare accessibility, the company stands out in the rapidly evolving healthtech sector, positioning itself as a compelling investment opportunity for institutional investors seeking both sustainable growth and positive social impact.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?